- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06264726
CommunityRx-hart- en vaatziekten (CRx-CVD)
CommunityRx-hart- en vaatziekten: implementatie van de HealtheRx om de ongelijkheid op gezondheidsgebied op het platteland van Oost-Noord-Carolina te verminderen
The goal of this single arm pre-test post-test design study is to test the impact of providing patients with information about community-based resources to address health-related social needs and cardiometabolic health in rural African American patients. The main question it aims to answer is:
• What is the effectiveness of community resource information on patient self-efficacy to use community resources?
Participants will be given:
- A personalized "HealtheRx" resource with information about community resources related to food, housing, utility support, transportation, and crisis support. The HealtheRx is personalized for patients based on their age and zip code.
- Access to a community resource navigator for support with using the HealtheRx upon request
- 2 text messages with reminders about the HealtheRx and access to the community resource navigator
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
North Carolina
-
Rocky Mount, North Carolina, Verenigde Staten, 27801
- OIC Family Medical Center - Fairview
-
Rocky Mount, North Carolina, Verenigde Staten, 27804
- OIC Family Medical Center - Happy Hill
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
patient
-
African American
-
age 2 or older
-
Have at least one cardiometabolic condition:
- Overweight (BMI greater than or equal to 25 kg/m^2);
- Obesity (BMI greater than or equal to 30 kg/m^2);
- ICD-9 or 10 diagnostic code for overweight or obesity
- Adult prehypertension (SBP 120 to 129 and DBP greater than 80 mmHg);
- Adult hypertension (SBP greater than or equal to130 or DBP = 80 mmHg);
- Pediatric Prehypertension (SBP or DBP greater than or equal to 90th but <95th percentile)
- Pediatric Hypertension (SBP or DBP greater than or equal to 95th percentile);
- ICD-9 or 10 diagnostic code for hypertension
- Adult and Pediatric Prediabetes (Fasting glucose 100-125 mg/dL or OGTT 140-199 mg/dL)
- Adult and Pediatric Diabetes (FPG greater than or equal to126 mg/dL (7.0 mmol/L) or OGTT greater than or equal to 200 mg/dL (11.1mmol/L) or HgbA1C greater than or equal to 6.5);
- ICD-9 or 10 diagnostic code for diabetes, pre-diabetes or elevated glucose, or gestational diabetes;
- Adult and Pediatric Total cholesterol (>200mg/dL; LDL >130mg/dL; HDL < 35 mg/dL; TG greater than or equal to150mg/dL);
- ICD-9 or 10 diagnostic code for hyperlipidemia
Exclusion Criteria:
- Unable to read, speak or understand English
- Unable to receive text message or email communications
- Living in the same household as someone already enrolled in the CRx-CVD study
- Adults with limited life expectancy (e.g., advanced cancer, end stage liver disease, hospice)
- Adults receiving treatment for cancer
- Adults living in skilled nursing facilities
- Dementia/other significant cognitive impairment
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intervention Group
This group will receive the intervention |
CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Participant Self-efficacy for Finding Community Resources
Tijdsspanne: Baseline, up to 6 months
|
Change in self-efficacy for finding community resources is measured using one item constructed from Bandura's Self-Efficacy Scale which asks, "How confident are you in your ability to find resources in your community that help you manage your health?" Responses will be assessed on a 5-point Likert scale ranging from 1= "not at all confident" to 5= "completely confident." Lower scores indicate lower levels of confidence, and higher scores indicate higher levels of confidence. |
Baseline, up to 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Participant Knowledge of Community Resources
Tijdsspanne: Baseline, up to 6 months
|
Change in participant knowledge of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking, "For each place that I list, please tell me if you know of places like this in your community: [insert community resource]." The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
|
Change in Participant Utilization of Community Resources
Tijdsspanne: Baseline, up to 6 months
|
Change in participant utilization of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking participants "Have you received services from places like this for you or your household in the last 6 months?" The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Gaurav Dave, MBBS, DrPH, Unviersity of North Carolina at Chapel Hill
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 23-0254
- R01HL150909 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD-tijdsbestek voor delen
Beginning 9 and continuing for 36 months following publication
IPD-toegangscriteria voor delen
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- ANALYTIC_CODE
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .